120 results on '"Urtasun, Raul"'
Search Results
2. Chemical Modifiers of Radiation Response
3. Contributors
4. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma
5. Regarding “Abbreviated Course of Radiation Therapy in Older Patients with Glioblastoma Multiforme: A Prospective Randomized Clinical Trial”
6. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data
7. HYPOXIC CELLS IN HUMAN TUMORS
8. Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer
9. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404
10. Investigations with Nitroimidazoles in Clinical Oncology
11. The Mer Minus Phenotype, Patient Response to Nitrosoureas, and Protooncogene Activation in Human Glioblastomas
12. 213: Serial Magnetic Resonance Spectroscopy Imaging Predicts Clinical Outcomes in High-Grade Glioma During and After Post-Operative Radiotherapy
13. A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors
14. Misonidazole and CCNU chemotherapy for recurrent primary brain tumor
15. Radiologically Occult Pulmonary Lymphangitic Carcinomatosis Detected by 67Gallium-Citrate Scintiscan
16. Chemotherapy for high-grade glioma
17. Dr. Felix Leborgne, 1935–2009
18. Assessment of Extended-Field Radiotherapy for Stage IIIC Endometrial Cancer Using Three-Dimensional Conformal Radiotherapy, Intensity-Modulated Radiotherapy, and Helical Tomotherapy
19. In Reply
20. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404
21. E-15. Imaging hypoxic micro-regions of lung cancers
22. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study
23. Impact of Adding Concurrent Chemotherapy to Hyperfractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
24. Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14
25. 122 Failure patterns by prognostic group as determined by recursive partitioning analysis (RPA) of 1547 on four radiation therapy oncology group studies in operable non-small cell lung cancer(NSCLC)
26. 2161 The impact of radiation dose and fractionation on the risk factor of radiation pneumonitis on four radiation therapy oncology group (RTOG) lung cancer trials
27. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, phase I–II study
28. 3 Imaging response is highly predictive of survival of malignant glioma patients treated with standard or hyperfractionated RT and carmustine in RTOG 9006
29. 102 The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis
30. 4 Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06
31. Physical Fitness of Patients with Small Cell Lung Cancer
32. A Radiation Therapy Oncology Group experience: chemotherapy/radiation therapy of lung cancer
33. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme
34. Radiosensitivity testing of human primary brain tumor specimens
35. Heterogeneity in response to treatment with buthionine sulfoximine or interferon in human malignant glioma cells
36. Five-Year Survival After Hyperfractionated Radiation Therapy for Non-Small-Cell Carcinoma of the Lung (NSCCL)
37. A randomized phase iii protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916)
38. Final report of the phase i trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03
39. Imaging Tumor Hypoxia and Tumor Perfusion.
40. Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
41. Radiation and High-Dose Metronidazole in Supratentorial Glioblastomas
42. Treatment of Infiltrating Bladder Cancer by Cobalt60Radiation: Recurrence of Tumor in Bladder after Initial Disappearance
43. Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report.
44. Tumor growth delay studies in patients with multiple metastatic nodules: Practical difficulties
45. Hypofractionated radiotherapy with or without misonidazole for the treatment of brain metastases
46. Clinical Phase I Study of the Hypoxic Cell Radiosensitizer RO-07-0582, A 2-Nitroimidazole Derivative
47. Phase 1 Study of High-Dose Metronidazole: A SpecificIn VivoandIn VitroRadiosensitizer of Hypoxic Cells
48. Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas
49. Hyperfractionation in the radiation therapy of unresectable non-oat cell carcinoma of the lung: Preliminary report of a RTOG pilot study
50. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.